LP-184 (Compound 6), referred to as an acylfulvene analog, demonstrates the ability to inhibit tumor growth with noteworthy anti-cancer efficacy observed across multiple cell lines, including ovarian, colon, prostate, and pancreatic.

HT29 cells:0.68 μM (IC50), OVCAR-3 cells:0.6 μM (IC50), AsPC-1 cells:16 μM (IC50), PC3:0.14 μM (IC50)

LP-184 inhibits the growth of HT29, OVCAR-3, AsPC-1 and PC-3, with GI 50 s of 0.68, 0.6, 16 and 0.14 μM, respectively[1]. LP-184 displays IC 50 s of 800nM and 210 nM for anti-cancer activitie in the thymidine incorporation into cellular DNA (2 hour) and Trypan blue (48 hour) assay[1].

LP-184 (7.5 and 10 mg/kg; i.p.; 21 day) has potent 15 anti-tumor activity against MV522 tumors, producing 4/6 and 5/5 partial responses, respectively[1]. Animal Model: Mice (MV522 tumors)[1]Dosage: 7.5 and 10 mg/kg Administration: I.p; 21day Result: Effective agent for human anti-tumor therapy.